Quantcast
Last updated on April 23, 2014 at 13:11 EDT

Latest Catechol-O-methyl transferase Stories

2013-07-30 12:28:17

Once-Daily Dopamine Agonists Will Progressively Dominate This Market-Leading Drug Class, According to a New Report from Decision Resources BURLINGTON, Mass., July 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of key current brands and the launch of three new therapies will help sustain the Parkinson's disease (PD) market throughout the 2012-2022 forecast period,...

2013-06-19 08:29:22

NESS ZIONA, Israel, June 19, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, were presented at the 2013 International Congress of Parkinson's Disease and Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that...

2013-03-20 08:28:05

BALTIMORE, March 20, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights to develop, register and commercialize agents that inhibit catechol-O-methyltransferase inhibitors ("COMT inhibitors"), previously discovered and owned by Merck, known as MSD outside the United States and Canada. (Logo:...

Placebo Effect Research: Important Implications For Patient Care
2012-10-24 12:37:27

Lee Rannals for redOrbit.com — Your Universe Online For the first time, researchers have identified genetic differences between placebo responders and non-responders. The new findings demonstrate that genetic differences that account for variations in the brain's dopamine levels help determine the extent of a person's placebo response. This discovery has important implications for patient care, and could also prove to be a significant benefit to researchers in designing and...

2010-11-08 15:08:23

A difference in a single gene is associated with a significantly increased willingness to donate Do you like to do good things for other people? If so, your genes might be responsible for this. At least, the results of a study conducted by researchers of the University of Bonn suggest this. According to the study, a minute change in a particular gene is associated with a significantly higher willingness to donate. People with this change gave twice as much money on average to a charitable...

2010-04-19 15:34:08

ST. PAUL, Minn. "“ New research shows a gene variant may help protect the memory and thinking skills of older people. The research will be published in the April 20, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology. "This is the first study to identify a protective relationship between this gene variant and cognitive function," said study author Alexandra Fiocco, PhD, with the University of California, San Francisco. For the study,...

2010-02-25 11:00:00

The 1994 genocide in Rwanda resulted in the mass killing of up to one million people over the course of about 100 days. Although the exact death toll is unknown, experts estimate that as much as 20% of the country's entire population was murdered. There can be no doubt or surprise then that some of the survivors developed posttraumatic stress disorder, or PTSD, an anxiety disorder that can develop after witnessing or experiencing a traumatizing event, such as abuse, war, or natural disaster....

2009-12-09 03:24:00

LONDON, Dec. 9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. With the introduction of newer dopamine agonists as well as fresh recommendations and treatment guidelines that call for using dopamine agonists as first-line therapy, the market is experiencing a...

2009-07-21 14:18:28

Placebos are a sham "” usually mere sugar pills designed to represent "no treatment" in a clinical treatment study. The effectiveness of the actual medication is compared with the placebo to determine if the medication works.And yet, for some people, the placebo works nearly as well as the medication. How well placebos work varies widely among individuals. Why that is so, and why they work at all, remains a mystery, thought to be based on some combination of biological and psychological...

2009-05-01 13:58:17

Genetic differences explain why some are predisposed to shock and kidney troubles; gene test guides treatment post operation Genetic differences can explain why some patients undergoing heart surgery later experience shock and kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that performing a genetic test on patients before they have surgery can help guide treatment after they leave the...